# Beyond the Skin: Nail Clues to a Bone Disease

**Authors:** Mariana Costa, Catarina Tavares, Cristina Alves, Paulo Coelho, João Nascimento

PMC · DOI: 10.7759/cureus.99174 · Cureus · 2025-12-14

## TL;DR

A case study shows a child with bone disease and nail changes linked to psoriasis, highlighting the importance of thorough physical exams in diagnosing rare inflammatory conditions.

## Contribution

This case emphasizes the association between CRMO and psoriasis, with nail dystrophy as an early diagnostic clue.

## Key findings

- CRMO was diagnosed in a child with multifocal bone lesions and nail dystrophy.
- Treatment with naproxen, methotrexate, and calcitriol led to full remission.
- Nail changes, such as trachyonychia, can precede skin symptoms in psoriasis.

## Abstract

Chronic recurrent multifocal osteomyelitis (CRMO) is a rare autoinflammatory bone disorder that predominantly affects children, and approximately 25% patients also present with an associated inflammatory condition. Most patients respond to nonsteroidal anti-inflammatory drugs, but refractory cases may need corticosteroids, bisphosphonate therapy, or disease-modifying antirheumatic drugs (DMARDs) like methotrexate, sulfasalazine, tumor necrosis factor-alpha (TNF-α) inhibitors, or even anti-interleukin-1 (anti-IL-1) blockers. We report the case of a previously healthy nine-year-old girl presenting with a four-week history of right hip pain and limping, associated with recent swelling and pain over the left sternoclavicular joint. There was no fever or systemic symptoms. Laboratory tests showed elevated inflammatory markers, with negative antinuclear antibody and HLA-B27. Multifocal inflammatory bone lesions involving the right femoral neck, left clavicle, left proximal tibia, and right pubic symphysis were identified on imaging, consistent with CRMO. Bone biopsy excluded malignancy. Physical examination showed dystrophic changes in all fingernails, with a history of nail pitting for one year, leading to the diagnosis of CRMO associated with psoriasis. Treatment with naproxen, topical calcitriol, and methotrexate resulted in complete clinical remission and resolution of nail dystrophy within eighteen months. This case highlights the importance of recognizing CRMO as part of the psoriatic disease spectrum in children presenting with multifocal bone pain and nail changes. As reported in the literature, CRMO is often associated with other inflammatory disorders, such as psoriasis, with an estimated prevalence of around 4%. Moreover, a thorough physical examination was essential in this case, allowing the identification of trachyonychia or twenty-nail dystrophy, a potential manifestation of conditions such as alopecia areata, lichen planus, or psoriasis, which may precede cutaneous lesions and, in 1-5% of patients, may be the only manifestation of the disease, making its diagnosis particularly challenging.

## Linked entities

- **Chemicals:** naproxen (PubChem CID 1302), calcitriol (PubChem CID 5280453), methotrexate (PubChem CID 4112)
- **Diseases:** Chronic recurrent multifocal osteomyelitis (MONDO:0009813), psoriasis (MONDO:0005083), alopecia areata (MONDO:0004907), lichen planus (MONDO:0006572)

## Full-text entities

- **Genes:** TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, HLA-B (major histocompatibility complex, class I, B) [NCBI Gene 3106] {aka AS, B-4901, HLAB}
- **Diseases:** nail dystrophy (MESH:D009260), inflammatory (MESH:D007249), bone pain (MESH:D010146), fever (MESH:D005334), cutaneous lesions (MESH:D009059), psoriatic disease (MESH:D015535), swelling (MESH:D004487), psoriasis (MESH:D011565), Bone Disease (MESH:D001847), lichen planus (MESH:D008010), autoinflammatory bone disorder (MESH:D056660), CRMO (MESH:C535456), malignancy (MESH:D009369), twenty-nail dystrophy (MESH:C562907), alopecia areata (MESH:D000506)
- **Chemicals:** methotrexate (MESH:D008727), bisphosphonate (MESH:D004164), sulfasalazine (MESH:D012460), naproxen (MESH:D009288), calcitriol (MESH:D002117)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12800714/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12800714/full.md

## References

14 references — full list in the complete paper: https://tomesphere.com/paper/PMC12800714/full.md

---
Source: https://tomesphere.com/paper/PMC12800714